Genetic Analysis of Liver Cancer
Summary
Liver cancer is a leading cause of cancer deaths worldwide. While the molecular pathogenesis of liver cancer has been extensively studied, less is known about how the molecular biology of liver cancer influences clinical outcome and treatment response. We are developing a translational research program that will characterize molecular changes in liver cancer. We plan to use molecular information obtained from studying liver tumor tissues to develop new diagnostics and treatment regimens for patients with these cancers. The experimental approach will require freezing fresh tumor tissues obtained from surgical procedures, which will be subsequently used for analysis of DNA, protein and mRNA expression. Many patients with liver cancer are referred to the Stanford Liver Tumor Board for consultation and treatment recommendations. We propose to gather tissue samples from those who subsequently undergo biopsy, liver resection surgery, or transplant surgery.
Study Design
Observational Model: Cohort, Time Perspective: Prospective
Conditions
Liver Cancer
Location
Stanford University School of Medicine
Stanford
California
United States
94305
Status
Terminated
Source
Stanford University
Results (where available)
Links
- Source: http://clinicaltrials.gov/show/NCT00768001
- Information obtained from ClinicalTrials.gov on February 14, 2012
Medical and Biotech [MESH] Definitions
Liver Neoplasms
Tumors or cancer of the LIVER.
Seer Program
A cancer registry mandated under the National Cancer Act of 1971 to operate and maintain a population-based cancer reporting system, reporting periodically estimates of cancer incidence and mortality in the United States. The Surveillance, Epidemiology, and End Results (SEER) Program is a continuing project of the National Cancer Institute of the National Institutes of Health. Among its goals, in addition to assembling and reporting cancer statistics, are the monitoring of annual cancer incident trends and the promoting of studies designed to identify factors amenable to cancer control interventions. (From National Cancer Institute, NIH Publication No. 91-3074, October 1990)
Aflatoxin M1
A 4-hydroxylated metabolite of AFLATOXIN B1, one of the MYCOTOXINS from ASPERGILLUS tainted food. It is associated with LIVER damage and cancer resulting from its P450 activation to the epoxide which alkylates DNA. Toxicity depends on the balance of liver enzymes that activate it (CYTOCHROME P-450) and others that detoxify it (GLUTATHIONE S TRANSFERASE) (Pharmac Ther 50.443 1991). Primates & rat are sensitive while mouse and hamster are tolerant (Canc Res 29.236 1969).
P-dimethylaminoazobenzene
A reagent used mainly to induce experimental liver cancer. According to the Fourth Annual Report on Carcinogens (NTP 85-002, p. 89) published in 1985, this compound "may reasonably be anticipated to be a carcinogen." (Merck, 11th ed)
End Stage Liver Disease
Final stage of a liver disease when the liver failure is irreversible and LIVER TRANSPLANTATION is needed.
Clinical Trials
A Phase I Study of Pazopanib in Adult Patients With Liver Cancer
Liver cancer is a good target for anti-angiogenic treatments such as pazopanib. The effect of pazopanib in patients with liver cancer are unknown. This study is designed to evaluate the...
Tamoxifen in Treating Patients With Primary Liver Cancer
RATIONALE: Estrogen can stimulate the growth of cancer cells. Hormone therapy using tamoxifen may fight liver cancer by blocking the absorption of estrogen. It is not yet known whether rec...
Therasphere® for Treatment of Unresectable Primary Liver Cancer and Metastatic Liver Cancer
The purpose of this protocol is to provide supervised and limited access to Therasphere® treatment for patients with primary liver cancer and chemotherapy refractory liver metastasis who...
Cryosurgery in Treating Patients With Liver Cancer or Liver Metastases
RATIONALE: Cryosurgery kills cancer cells by freezing them during surgery. PURPOSE: Phase I/II trial to study the effectiveness of cryosurgery in treating patients with unresectable prima...
Viral & Host Factors Associated With Hepatitis B Virus-related Hepatocelluar Carcinoma
Adult liver cancer is the third leading cause of cancer deaths worldwide. The major risk factor for liver cancer is hepatitis B virus (HBV) infection. The purpose of the study is to sequen...
PubMed Articles
Insulin-like growth factors and liver cancer risk in male smokers.
Background:The liver is the primary source of circulating insulin-like growth factor (IGF)-I, yet the relation between IGFs and liver cancer is uncertain.Methods:In a case-cohort study within a cohort...
Liver transplantation: A simple inflammation marker predicts liver cancer prognosis.
Cell Therapies for Liver Diseases.
Cell therapies, which include bioartificial liver support and hepatocyte transplantation, have emerged as potential treatments for a variety of liver diseases. Acute liver failure (ALF), acute-on-chro...
Different incidence of synchronous liver metastasis between proximal and distal colon cancer.
PURPOSE: The clinicopathological features of colon cancer differ between proximal and distal sites; however, the influence of tumor location on liver metastasis has not been full...
Liver cancer incidence and mortality in China, 2009.
Liver cancer is one of the most common cancers and a leading cause of cancer deaths in China. To aid the government in establishing a control plan for this disease, we provided real-time surveillance...
